<DOC>
	<DOCNO>NCT01002716</DOCNO>
	<brief_summary>The efficacy vaccination influenza patient rheumatoid arthritis assess use humoral response . However , cellular immunity another important pathway response vaccination . The purpose study evaluate degree cellular immunity response influenza vaccination . Patient rheumatoid arthritis healthy control participate study , undergo clinical evaluation day vaccination 4 week . The humoral cell immunity response assess day vaccination 4 week later</brief_summary>
	<brief_title>Cell Immunity Response Vaccination Against Influenza Patients With Rheumatoid Arthritis</brief_title>
	<detailed_description>Sixty patient RA 30 healthy , age match control participate study . After sign informed consent , subject vaccinate inactivated split virion vaccine recommend WHO next fall . Patients evaluate weel 0 6 week later . Clinical evaluation base Disease Activity Score 28 ( DAS 28 ) include number swell tender joint , visual global evaluation physician , ESR CRP Blood collect day vaccination 6 week later . Preparation peripheral blood mononuclear cell Blood sample obtain prior 4 week vaccination . Peripheral blood mononuclear cell ( PBMC ) isolate centrifugation heparinized blood Lymphoprep gradient ( Nycomed , Oslo , Norway ) . Cells wash twice tissue culture medium RPMI ( RPMI1640-Hepes Glutamax-I , GIBCO BRL , NY , USA ) resuspend concentration 2 106/ml RPMI 1640 supplement 10 % heat inactivated fetal bovine serum ( FBS ) ( GIBCO BRL , NY , USA ) . ELISPOT assay The 96-well PVDF ( polyvinylidene difluoride , Millipore Corp. , MA , USA ) plat prewet 70 % EtOH , coat 100 l/well anti-human IFN- monoclonal antibody ( mAb ) 1-D1K , dilute 15 g/ml sterile filter phosphate-buffered saline ( PBS ) . The plate keep overnight 4°C . A total 100 000 PBMC plus 5 l/well ( 1 g/ml ) peptides added well duplicate condition incubate 24 h 37°C 5 % CO2 . After incubation plate wash PBS 100 l biotinylated mAb ( 7-B6-1-biotin , Mabtech AB ) , dilute filter PBS 0.5 % FBS concentration 1 g/ml add well . The plate incubate 2 h room temperature , wash PBS incubate 100 l/well streptavidine-alkaline phosphatase ( Mabtech AB ) dilute 1-1000 PBS 0.5 % FBS 1 h room temperature . After wash , cell develop add 100 l/well colorimetric substrate ( BCIP/NBT-plus , Mabtech AB ) count ELISPOT reader . Each spot produce single IFN- secrete T-cell-spot-forming cell ( SFC ) . All test perform duplicate mean value calculate . A response consider positive number spot well peptide-stimulated cell , subtraction background ( well without peptide stimulation ) , least two-fold great number background spots14 20/106 SFC . Detection intracellular cytokine production flow cytometry The intracellular staining method use identify phenotype INF- produce T cell activate peptide stimulation . The staining perform use protocol describe Rauser et al.15 PBMC stimulate 6 h 1 g/ml influenza peptide . Brefeldin A ( 10 g/ml , Sigma-Aldrich , St Louis , MO ) add last 4 h incubation . A positive control obtain stimulate cell 0.5 g/ml PMA ( Phorbol 12-myrestate 13-acetate ) 1 g/ml Ionomycin ( Sigma-Aldrich , St Louis , MO , USA ) . The cell permeabilized stain fluorochrome-labeled anti-CD3 , anti-CD4 anti-CD8 anti-IFN- antibody ( Becton Dickinson , San Jose , CA , USA ) . Samples analyze flow cytometry use FACSCalibur ( Becton Dickinson ) . The positive limit test 0.05 % IFN produce T cell . Proliferation specific CD4+ CD8+ Cellular response evaluate simultaneously analyze proliferation specific T CD4+ CD8+ lymphocytes upon stimulation antigen three virus strain present vaccine production activation Th1 cytokines cell . Briefly , simultaneously analyze proliferation cytokine production influenza specific T cell , peripheral blood mononuclear cell obtain T0 T1 donor , stain fluorescent nuclear dye carboxyfluorescein succinimidyl ester ( CFSE ; Molecular Probes ) culture duplicate presence peptide HA virus strain contain influenza virus vaccine use study control peptide 72 h. At end incubation culture stop brefeldin , cell resuspend , stain fluorochrome-conjugated anti-CD8 anti-interferon-γ ( IFN-γ ) monoclonal antibody ( Becton &amp; Dickinson ) analyze mean six colour flow-cytometer ( FACSCanto-Becton &amp; Dickinson ) FACS DIVA software . As every cell division nuclear fluorescence halve , proliferate cell fall leave quadrant cytogram , division less fluorescence . IFN-γ produce cell fall upper quadrant cytograms . Cells upon specific influenza peptide control peptide stimulation proliferate actively produce IFN-γ ( Th1 cytokine ) fall upper leave quadrant cytogram . They measure frequency ( proliferate IFN-γ-producing cells/total T CD4+ CD8+ lymphocytes ) . Haemagglutination inhibition test The immunogenicity vaccine test Haemagglutination inhibition ( HI ) test . Influenza virus two important surface glycoprotein : haemagglutinin ( HA ) neuraminidase ( NA ) . Antigenic classification subtyping influenza virus base two glycoprotein . HA play key role virus cell entry bind cell surface receptor , find also red blood cell certain specie . Binding red cell result haemagglutination , observe carpet agglutinate red cell bottom tube microtitre well . In HI test , antibody direct viral haemagglutinins block virus binding blood cell thus inhibits haemagglutination reaction . The pre- post immunization HI antibody test Central Virology Laboratory Israeli Ministry Health use HI test accord standard WHO procedure 16 . Sera separate , code label , store -20°C test . Sera treat receptor destroy enzyme cholera filtrate remove non-specific inhibitor , Turkey red blood cell remove non-specific agglutinin . The treated serum test HI test three antigen include vaccine : A/California ( CAL ) , B/Shangai ( SHAN ) A/New Caledonia ( NC ) . The work dilution ( test dose ) antigen contain four haemagglutinin unit 25 µl antigen . Test dose dilute phosphate buffer saline ( PBS ) add serial dilution antiserum . The haemagglutinin inhibition titer determine high dilution serum completely inhibits haemagglutination red blood cell . The titer antiserum show inhibition record &lt; 10 . Humoral response define either fourfold rise titer , rise non-protective baseline level &lt; 1/40 1/40 HI antibody four week vaccination 17,18 . Geometric mean titer antibody calculated ass immunity whole group . Primary Endpoint study : proportion cell produce Interferon gamma Patients rheumatoid arthritis control Secondary Endpoint : Safety vaccine</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Rheumatoid arthritis Allergy egg</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2009</verification_date>
	<keyword>rheumatoid influenza vaccine cell immunity</keyword>
</DOC>